↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of brivaracetam and its potential in the treatment of epilepsy

Overview of attention for article published in Neuropsychiatric Disease and Treatment, November 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
21 Mendeley
Title
Profile of brivaracetam and its potential in the treatment of epilepsy
Published in
Neuropsychiatric Disease and Treatment, November 2015
DOI 10.2147/ndt.s60849
Pubmed ID
Authors

Edoardo Ferlazzo, Emilio Russo, Laura Mumoli, Chiara Sueri, Sara Gasparini, Caterina Palleria, Angelo Labate, Antonio Gambardella, Giovambattista De Sarro, Umberto Aguglia

Abstract

Brivaracetam (BRV) (UCB 34714) is currently under review by the US Food and Drug Administration and European Medicines Agency for approval as an add-on treatment for adult patients with partial seizures. Similar to levetiracetam (LEV), BRV acts as a high-affinity ligand of the synaptic vesicle protein 2A, however, it has been shown to be 10- to 30-fold more potent than LEV. Moreover, BRV does not share the LEV inhibitory activity on the high voltage Ca(2+) channels and AMPA receptors, and it has been reported to act as a partial antagonist on neuronal voltage-gated sodium channels. The pharmacokinetic profile of BRV is favorable and linear, and it undergoes an extensive metabolism into inactive compounds, mainly through the hydrolysis of its acetamide group. Furthermore, it does not significantly interact with other antiepileptic drugs and more than 95% is excreted through the urine, with an unchanged fraction of 8%-11%. BRV has a half-life of approximately 8-9 hours and it is usually given twice daily. To date, a wide range of experimental studies have reported the effectiveness of BRV with regards to partial and generalized seizures. In humans, six randomized, placebo-controlled trials and two meta-analyses highlighted the efficacy, or good tolerability, of BRV as an add-on treatment for patients with uncontrolled partial seizures. A wide dose range of BRV has been evaluated in those trials (5-200 mg), but the most suitable for clinical use appears to be 50-100 mg/day. The most common adverse reactions to BRV are mild to moderate, transient, often improve during the course of the treatment, and mainly consist of central nervous system symptoms, such as fatigue, dizziness, and somnolence. The aim of this paper is to critically review the literature data regarding experimental animal models and clinical trials on BRV, and to define its potential usefulness for the clinicians who manage patients with epilepsy.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 5%
Germany 1 5%
Unknown 19 90%

Demographic breakdown

Readers by professional status Count As %
Professor 4 19%
Professor > Associate Professor 3 14%
Researcher 3 14%
Other 2 10%
Student > Master 2 10%
Other 3 14%
Unknown 4 19%
Readers by discipline Count As %
Medicine and Dentistry 4 19%
Neuroscience 3 14%
Pharmacology, Toxicology and Pharmaceutical Science 2 10%
Chemistry 2 10%
Agricultural and Biological Sciences 2 10%
Other 3 14%
Unknown 5 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2015.
All research outputs
#7,970,409
of 14,687,926 outputs
Outputs from Neuropsychiatric Disease and Treatment
#988
of 2,442 outputs
Outputs of similar age
#141,864
of 359,380 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#44
of 68 outputs
Altmetric has tracked 14,687,926 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,380 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.